Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pancreas Adenocarcinoma
- Sponsor
- National Cancer Center, Korea
- Enrollment
- 420
- Locations
- 1
- Primary Endpoint
- Clinical applicability of KRAS mutations
- Status
- Active, not recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Detailed Description
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Investigators
Sang Myung Woo
Chief, Senior Scientist
National Cancer Center, Korea
Eligibility Criteria
Inclusion Criteria
- •Patients with pathologically confirmed pancreatic adenocarcinoma.
Exclusion Criteria
- •Patients disagree with the study.
Outcomes
Primary Outcomes
Clinical applicability of KRAS mutations
Time Frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
Discovery of biomarkers through ctDNA panel
Time Frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.